Dossier assessment

Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-130
Last updated

Report documents

  1. Extract of dossier assessment

    Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 321 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-130_en
  2. Dossier assessment

    Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 706 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-130

Dossier assessment

Indication:

Adult patients with refractory or relapsed follicular lymphoma who have received at least 2 prior systemic therapies

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A23-130
Commission
Commission awarded on 15.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-130_en

Connected Projects

  1. Dossier assessment

    Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-132
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Zanubrutinib (marginal zone lymphoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-131
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Zanubrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-130
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Zanubrutinib (Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-169
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form